In light of the pandemic situation events until September 2021 are cancelled. We will inform customers directly when the events are rescheduled.    
COVID CANCELLED: Project Management in Human Resources,   Boston MA, Jan 6-8, 2021
COVID CANCELLED: InterDrone, The International Drone Conference,   Cambridge MA, Jan 11-13, 2021
COVID CANCELLED: Supplier Management for Medical Device Manufacturers,   Cambridge MA, Feb 2-4, 2021
COVID CANCELLED: US Immigration Compliance Strategies,   Boston MA, Feb 15-18, 2021
COVID CANCELLED: Project Management Training,   Boston MA, Mar 3-5, 2021
COVID CANCELLED: Internal Audit, Fraud Risk Assessment Workshop,   Boston MA, Mar 22-25, 2021
COVID CANCELLED: Agile / Scrum Training,   Boston MA, Apr 12-14, 2021
COVID CANCELLED: Validation, Verification and Transfer of Analytical Methods,   Boston MA, Apr 19-21, 2021
COVID CANCELLED: Computer System Validation - Reduce Costs and Avoid 483s,   Boston MA, May 10-12, 2021
COVID CANCELLED: SharePoint Technology Conference,   Boston MA, May 26-28, 2021
COVID CANCELLED: Employment Laws Certificate Program,   Boston MA, Jun 7-9, 2021
Following events are tentatively planned but may be rescheduled, based on CDC guidelines or attendee registration interest .    
TENTATIVE: 21 CFR Part 11 Compliance,   Boston MA, Sep 22-24, 2021
TENTATIVE: Quality Control Laboratory Compliance,   Boston MA, Oct 6-8, 2021
TENTATIVE: Analytical Instrument Qualification and System Validation,   Boston MA, Nov 15-17, 2021
TENTATIVE: FDA's New Import Program for 2021,   Boston MA, Dec 7-9, 2021

Boston Professional Events List

5th Annual RAS-Targeted Drug Development Summit

Sep 26, 2023 - 08:30 AM - Sep 28, 06:00 PM
Hanson Wade
Hilton Boston Back Bay
40, Dalton St

ZIP: 02115
Phone: +16174554188

Ticket Price: USD 2599.00 - USD 6046.00

With the approval of the second-ever KRAS G12C inhibitor, the field can once again celebrate irrevocable proof that RAS is druggable! However, with so many KRAS G12C drugs in clinic, the field is now turning its eyes to the next generation of RAS therapies, specifically those that can target more mutations, more RAS isoforms, and more indications.

And so, the 5th RAS Targeted Drug Development Summit arrives as the only industry-dedicated, end-to-end forum to accelerate your best-in-class RAS therapies from conception through to commercialization.

As the only industry-dedicated, end-to-end meeting focused on the next-generation of drugs targeting RAS cancers, the 5th RAS Targeted Drug Development Summit will bring together 150+ key opinion leaders to accelerate RAS-targeted drug discovery, advance pre-clinical drugs to clinic, and optimize translational and clinical development.

Industry leaders such as Mirati Therapeutics, Revolution Medicines, Amgen, Novartis, Roche and Loxo Oncology@Lilly will deliver technical, data-led clinical updates and workshops on the translational and clinical development track. On the other hand, expect to hear about promising candidates from the likes of BridgeBio, Biotheryx, Pfizer, and Genentech on the early discovery and pre-clinical track.

Use this exclusive opportunity to network with the key stakeholders and decision makers of the RAS industry including CXOs, VPs, Senior Directors and Global Leads of Oncology, Translational and Clinical Sciences, Chemistry and Biology as well as key academics and oncologists such as Frank McCormick, Channing Der, Chiara Ambrogio, Andrew Aguirre, Mark Awad and Poulikos Poulikakos.

Tickets: https://go.evvnt.com/1729218-2?pid=1052
Brochure: https://go.evvnt.com/1729218-3?pid=1052

Conference + Workshop Day (Track A or Track B) - Drug Developer Pricing: USD 4946.00,
Conference Only - Drug Developer Pricing: USD 2999.00,
Conference + Workshop Day (Track A or B) - Solution and Service Provider Pricing: USD 6046.00,
Conference Only - Solution and Service Provider Pricing: USD 3799.00,
Conference + Workshop Day (Track A or B) - Academic Pricing: USD 4246.00,
Conference Only - Academic Pricing: USD 2599.00


Speaker Details

Arjun Balar, Vice President - Global Clinical Development, Loxo Oncology, Saskia Brachmann, Associate Director and Senior Global Lead, Novartis, Emily Chan, Medical Director, Clinical Research, Amgen, Nicholas Endres, Principal Scientist, Genentech, Antreas Hindoyan, Director, Clinical Biomarkers and Diagnostics, Amgen , Greg Jones, Principal Scientist, Pfizer, Robert Norgard, Senior Scientist, Boehringer Ingelheim, Ahmadur Rahman, Senior Director - Clinical, Global Oncology, Research and Development Science Lead, Roche, Chinatsu Sakata-Sakurai, Vice President, Primary Focus Lead, Targeted Protein Degradation, Astellas Pharma, Andrea Wang-Gillam, Chief Medical Officer, Jacobio Pharmaceutical, Allison Zavitz, Lifecycle Leader, KRAS, Roche, Ashita Nayak, Executive Director, Marketing, Amgen, Steven Howard, Director, Chemistry, Astex Therapeutics, Ida Aronchik, Senior Director - Translational Sciences, Revolution Medicines, Pedro Beltran, Senior Vice President and Head of Biology ,BridgeBio and Oncology Therapeutics, Bridge Bioscience, Charly Chahwan, CSO, SyntheX, Aparajita, Chourasia Vice President, Biology, BioTheryx, Louis Denis, Chief Medical Officer, Verastem, Steven Fruchtman, President and Chief Executive officer, Chief Medical Officer, Onconova Therapeutics, Rie Schultz Hansen, CSO, Aelin Therapeutics, Lingyan Jiang, Senior Scientist II, Revolution Medicines, Shohei Koide, Co-Founder of Aethon Bio and Professor, Grossman School of Medicine NYU Langone Health, Hue Lam Vice, President of Preclinical Development, Affini-T Therapeutics, Shivani Malik, Associate Director, Kura Oncology, Andrew Norris, Co-Founder, CSO, BCN Biosciences, Jonathan Pachter, Chief Scientific Officer, Verastem, Gary Piazza Chief Scientist, ADT Pharmaceutical LLC and Director, Cancer Research Center Auburn University, Krishnaraj Rajalingam, Founder, KHR Biotec and Head of Cell Biology Unit, University of Mainz, Debra Ryan, Director, Medical Strategy, Mirati Therapeutics, Hugh Salter, Chief Scientific Officer and Vice President - Strategy and Translation, Anocca AB, Said Sebti, Co-Founder, Prescient Therapeutics and Associate Director of Basic Research, VCU Massey Cancer Center, Sunanda Singh, Founder and Chief Executive Officer, Singh Biotechnology, Giovanni Spagnolli, Co-Founder and Chief Technology Officer, Sibylla Biotech, Ali Tavassoli, CSO, Curve Therapeutics, Greg Verdine, Co-Founder, President, Chief Executive and Technology Officer, LifeMine Therapeutics, Kevin Yang, Associate Director of Translational Research, Revolution Medicines, Michelle Zhang, Chief Scientific Officer, Ikena Oncology, Terri Conneran, Founder, KRAS Kickers

Event Categories
Keywords: conference , Health , science


Events Calendar

27 28 29 30 31 1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Event Location


VIP Life Time Subscription to our Newsletters!